Skip to main content
CFRXNasdaqinactive

CONTRAFECT Corp

Biopharma developer (SEC filing verified)·CEO: Roger J. Pomerantz, M.D.

CFRX evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for CFRX—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

1.5/10

BioSniper Score

Based on 3 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

2.0 mo

Lead Asset

exebacase

Next Catalyst

—

Financial data as of Sep 30, 2023.

Tracking 1 pipeline candidate for CONTRAFECT Corp.

Run CONTRAFECT Corp through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available CONTRAFECT Corp facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 3 of 6 signals · derived from public data

Cash Runway0.6

2.0 months

Financial Health0.5

OCF -$9M · Net income -$5M

Pipeline MaturityN/A

No tracked pipeline phase

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Run my thesis on this company

Pipeline

Run my thesis on this company

Financials

Run my thesis on this company
925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.